“showed a trend”

At T0, patients who developed n-BSI showed a trend toward an increase of LBP (median, IQR, ng/mL) than those without n-BSI [34470 (27580-47790) vs 25050 (10334-49250), p=0.24] ( Figure 3A ).

The tricuspid annular plane systolic excursion showed a trend toward a decrease in the anhepatic phase compared to baseline (2.0 ± 0.9 cm vs. 2.4 ± 0.7 cm; P = 0.24) but with full recovery after reperfusion.

Short‐term (6 weeks) treatment did not significantly alter plaque size between groups, although warfarin showed a trend toward smaller plaques compared with control and dabigatran treatment ( p = .24 and p = .09 for warfarin vs control and DE, respectively; Figure 1B ).

Although Child’s B and C patients showed a trend to higher myostatin levels, these were not significantly different of those observed among Child’s A patients (KW = 2.83; p = 0.24).

Of note is that the burned group (n = 4) showed a trend toward reduced adipocyte count compared to unburned controls (p = 0.24).

They also showed a trend for higher serum levels of a-fetoprotein, which is a diagnostic marker of HCC ( p = 0.24).

While our cohort of ALK-positive NSCLC patients was heterogeneous in terms of their treatment history prior to blood collection, higher ALK autoantibody levels showed a trend toward more favorable overall survival outcomes (P=0.24, Figure 4 ), although there were several early censoring events in this analysis.

Finally, for the larvae coming from the PET 26° , no significant difference was found between the different TTs, even though the means showed a trend for lower mortality at higher temperatures (ANOVA F 2,57 = 1.453, p ‐value =0.24) (Figure 5 c).

Although not shown to be statistically significant, sites without the pharmacist intervention were analyzed during the same timeframe and showed a trend toward improvement in patient enrollment, from 3.2 to 4.9 patients per month ( p = .24) after the release of the weekly report.

This showed a trend towards improvement compared to baseline at 12 weeks with a mean (SE) decrease in score of −7 (5), p = 0.24 (ITT, Table 2 ), which was maintained to week 48 and to week 72 (after treatment had stopped), by ITT and PP analysis ( Figure 3 ).

The same allele T of IGF1 rs6214 showed a trend of association with longer lens thickness in both STM and NAI cohorts (β±SE=0.049±0.041 mm, p=0.240; and β±SE=0.06±0.03 mm, p=0.027, respectively, Table 4 ).

Intriguingly, patients of over 60 years showed a trend towards better GHS scores than the younger patients in follow-up care (74.14% vs. 64.72%, p = 0.241).

After 1 year of treatment, patients diagnosed with PsA were less likely to persist with secukinumab than those with AxSpA with an HR of 12.32 (95% CI 1.6–94.9, p = 0.016), obese patients showed a non-significant trend to discontinuation with respect to the non-obese with an HR of 2.54 (95% CI 0.99–6.50, p = 0.051) and women showed a trend toward a better retention rate that men with an HR of 0.29 (95% CI 0.04–2.28, p = 0.241).

PAM showed a trend for higher success than PAC, in both fully susceptible (ER = 95% vs ER = 91%, p = 0.241) and single-resistant strains (ER = 88% vs ER = 83%, p = 0.383) (Table 2 , Supplementary 6).

Although vertical DSM showed a trend toward worse BCVA compared to round DSM (estimate = 0.144 logMAR; P = 0.243), this difference was not statistically significant.

Comparing patients with and without shocks also showed a trend towards higher programmed VF zones (≥ 210 BPM) at end of study follow-up in the patients without shocks (79 vs. 89%; P = 0.243, Table 3 ), though not significant.

Specifically, the difference in the right PVS number showed a trend-level effect after FDR correction (FDR-adjusted P = 0.245, Cohen's d = 0.479), and the difference in the left DTI-ALPS index also demonstrated a trend-level effect after FDR correction (FDR-adjusted P = 0.074, Cohen's d = 0.513).

Patients who took acetazolamide showed a trend towards better MDI scores than patients on topiramate or without medication ( p = 0.246, supplementary Table 1 in ESM).

Results During the bracing phase, the IOFS showed a trend towards lower scores when compared to the casting phase for both cohorts ( p = 0.247 and p = 0.434, respectively).

The risk of CME development showed a trend toward lower CME rates in the FLACS group than the CPCS group, whether defined as appearance of cystoid changes near fovea on OCT imaging ( p =0.247) or using PREMED study criteria ( p =0.586).

Compared to CRT alone, the durvalumab combined with concurrent CRT group showed a trend toward improved PFS (median PFS: 13.8 vs. 9.4 months; HR = 0.85; 95% CI: 0.65–1.12; p = 0.247), without statistical significance [ 56 ].

Regarding the subgroup of patients with a TPS score > 50%, the parameter PET-Skewness also showed a trend in favor of patients with a value below the above-mentioned threshold (HR for disease progression or death, 0.57; 95% CI, 0.22 to 1.48; p = 0.247; Figure 5 A).

Survivors in our study showed a trend for shorter reperfusion times (minutes: 83.3 ± 40.6 vs. 98.4 ± 40.5; p = 0.25) and total CBP times (minutes: 215.8 ± 73.6 vs. 256.2 ± 125.9; p = 0.26) with a significantly shorter total operation time (minutes: 364.6 ± 97.1 vs. 449.1 ± 141.7; p = 0.002).

A pilot randomized controlled trial (RCT) evaluating an early on-demand strategy, triggered by persistent or unresolved organ failure, showed a trend toward reduced major complications/death (20% vs. 46.7%, P = 0.25) compared with standard care, though statistical significance was not achieved [ 15 ] .

In non‐gastrointestinal stromal tumor sarcomas, the dual test showed a trend toward higher rates of genotype‐matched therapy (4.3% vs. 2.6%, p = 0.25) and a significantly higher rate of molecular targeted therapy (4.3% vs. 1.5%, p = 0.03).